PharmaLex Group further strengthens senior regulatory expertise

The PharmaLex Group, a specialist provider of development consulting and scientific affairs, regulatory affairs, quality and compliance services, and pharmacovigilance appointed Dr Adam King to enhance the UK management team and provide a regulatory focus on mergers and acquisitions (M&A) for the Group.

Dr Adam King joins PharmaLex as Senior Director of Regulatory Affairs and Service Area Lead for Regulatory Activities related to M&A. King has nearly 30 years of experience working in the pharmaceutical industry, with more than 18 years regulatory affairs experience both in a global R&D environment and more recently regulatory consultancy.

In addition, he has extensive experience in radiopharmaceutical development, regulatory strategy development and oversight of the successful delivery of large scale regulatory affairs chemistry, manufacturing and control (CMC) programmes.

King said: "I am excited to be part of the PharmaLex team and to spearhead a delivery service area to offer my experience for current/prospective clients in supporting the regulatory activities related to M&A. I will be able to leverage the extensive experience and expertise, which already exists within the organisation."

King’s most recent experiences include leading a team of experienced regulatory consultants to successfully complete a large CMC compliance project working with one of the Top 5 Consumer Healthcare companies and taking regulatory oversight of a large scale CMC site transfer programme.

He has also been the R&D lead for the design and implementation of an electronic document management system (EDMS), publishing tools into a combined R&D and manufacturing environment.

Dr Kirsten Jacobs, Executive Vice President and Head of Global Regulatory Affairs at PharmaLex, said: "Adam’s appointment demonstrates our commitment to developing our existing regulatory team, helping to guide our growing customer base to regulatory milestone achievements.

"His wide ranging experience of activities needed for M&A will provide both the UK and global team with vital skills that enable us to provide our clients with added value."


You may also like